LDN-212854

• CAT Number: I001671
• CAS Number: 1432597-26-6
• Molecular Formula: C25H22N6
• Molecular Weight: 406.50
• Purity: ≥95%
• Target: TGF-β Receptor
• Solubility: DMSO: ≥ 30 mg/mL
• Storage: Store at -20°C
• IC50: 1.3 nM
• IUPAC Name: 5-[6-(4-piperazin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline
• InChI: InChI=1S/C25H22N6/c1-3-21(22-4-2-10-27-24(22)5-1)23-16-29-31-17-19(15-28-25(23)31)18-6-8-20(9-7-18)30-13-11-26-12-14-30/h1-10,15-17,26H,11-14H2
• InChIKey: BBDGBGOVJPEFBT-UHFFFAOYSA-N
• SMILES: C1CN(CCN1)C2=CC=C(C=C2)C3=CN4C(=C(C=N4)C5=C6C=CC=NC6=CC=C5)N=C3

LDN-212854（Cat No.:I001671）is a small molecule compound under investigation for its potential therapeutic applications, particularly in cancer treatment. It acts as a selective inhibitor of the enzyme indoleamine 2,3-dioxygenase 1 (IDO1), which plays a role in regulating immune responses by metabolizing tryptophan. By inhibiting IDO1, LDN-212854 aims to enhance the immune system’s ability to target and destroy tumor cells. This inhibition could improve the effectiveness of immunotherapies, particularly in cancers that exploit the IDO1 pathway for immune evasion. Research is ongoing to assess its safety and efficacy in clinical settings.